DNAI1 and primary ciliary dyskinesia: Significantly, half of these trials were terminated upon the conclusion of phase I. Ongoing clinical trials via LNP-mRNA to facilitate protein replacement therapies include mRNA-3927 from Moderna to facilitate enzyme therapy to treat propionic acidemia (NCT04159103), MRT5005 from Translate Bio for treating cystic fibrosis and restoring lung function (NCT03375047), and RCT1100 from Recode Therapeutics to treat primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene (NCT05737485).